Table 2.
Biochemical and radiographic responses expressed as changes in PSA level, TTV, SUV and RECIST in 38 patients after 177Lu-PSMA-617 radioligand therapy
| Response measure | Change after RLT (%), median (IQR) | Response, n (%) | |||
|---|---|---|---|---|---|
| Complete | Partial | Stable disease | Progressive disease | ||
| PSA | −43.98 (−84.67, 15.37) | 0 (0.0) | 18 (47.4) | 12 (31.6) | 8 (21.1) |
| TTV | −45.13 (−83.83, 4.41) | 2 (5.3) | 22 (57.9) | 8 (21.1) | 6 (15.8) |
| SUVmeana | −25.76 (−46.54, −6.14) | 2 (5.3) | 17 (44.7) | 17 (44.7) | 2 (5.3) |
| RECISTb | −11.25 (−33.94, 0.00) | 1 (2.6) | 9 (23.7) | 15 (39.5) | 5 (13.2) |
PSA prostate-specific antigen, TTV PSMA total tumor volume, SUVmean mean PSMA standardized uptake value, RECIST Response Evaluation Criteria in Solid Tumors, IQR interquartile range, RLT radioligand therapy
aLiver SUVmean: 3.1 (IQR 2.5–4.1) before RLT, 3.2 (IQR 2.6–3.8) after three cycles of RLT
bResponse evaluation was not possible in eight patients (21.1%) because they had no measurable target lesions according to RECIST 1.1